These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan. Hatake K; Ogura M; Takada K; Taniwaki M; Zhang F; Fujita T; Ando K Int J Hematol; 2017 Aug; 106(2):240-247. PubMed ID: 28421390 [TBL] [Abstract][Full Text] [Related]
4. A five-year follow-up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial. Offner F; Robak T; Janssens A; Govind Babu K; Kloczko J; Grosicki S; Mayer J; Panagiotidis P; Schuh A; Pettitt A; Montillo M; Werner O; Vincent G; Khanna S; Hillmen P Br J Haematol; 2020 Sep; 190(5):736-740. PubMed ID: 32236950 [TBL] [Abstract][Full Text] [Related]
5. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Ladyzynski P; Molik M; Foltynski P Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118 [TBL] [Abstract][Full Text] [Related]
6. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. Hillmen P; Janssens A; Babu KG; Kloczko J; Grosicki S; Manson S; McKeown A; Gupta I; Chang CN; Offner F Acta Oncol; 2016; 55(9-10):1115-1120. PubMed ID: 27494089 [TBL] [Abstract][Full Text] [Related]
7. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313 [TBL] [Abstract][Full Text] [Related]
8. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Elias L; Stock-Novack D; Head DR; Grever MR; Weick JK; Chapman RA; Godwin JE; Metz EN; Appelbaum FR Leukemia; 1993 Mar; 7(3):361-5. PubMed ID: 7680398 [TBL] [Abstract][Full Text] [Related]
9. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208 [TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022 [TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab: new indication. First line treatment of chronic lymphocytic leukaemia: continue to use oral chlorambucil. Prescrire Int; 2009 Apr; 18(100):60. PubMed ID: 19585719 [TBL] [Abstract][Full Text] [Related]
12. Ofatumumab: chronic lymphocytic leukaemia: a last resort. Prescrire Int; 2010 Oct; 19(109):201-3. PubMed ID: 21180369 [TBL] [Abstract][Full Text] [Related]
13. Pentostatin (Nipent) and chlorambucil with granulocyte-macrophage colony-stimulating factor support for patients with previously untreated, treated, and fludarabine-refractory B-cell chronic lymphocytic leukemia. Waselenko JK; Grever MR; Beer M; Lucas MA; Byrd JC Semin Oncol; 2000 Apr; 27(2 Suppl 5):44-51. PubMed ID: 10877052 [TBL] [Abstract][Full Text] [Related]
14. Optimal First-Line Therapy for Previously Untreated Chronic Lymphocytic Leukemia: The Case for Chemotherapy. Brown JR Oncology (Williston Park); 2015 Jun; 29(6):442, 444. PubMed ID: 26091679 [No Abstract] [Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Main C; Pitt M; Moxham T; Stein K Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488 [TBL] [Abstract][Full Text] [Related]